Catalyst overview
Research summary
This catalyst tracks a Phase 3 data readout for Zorevunersen in Dravet Syndrome. The expected timing is based on the latest available company guidance and may change.
EMPEROR Study. Partnership w/ Stoke Therapeutics. 8/11/25- First patient dosed. 9/2/25- Presented data at the 36th IEC. 10/9/25- New data presented at CNS'25. 01/11/26:- EMPEROR Ph3 enrollment completion now expected Q2 2026; data readout Mid-2027; rolling NDA planned H1 2027.
Verification
Confirm timing and program details against the company announcement or filing.